LPC constitutes only about 0.1% to 0.4% of all malignant tumors; therefore, it has not been evaluated clinically fully.[3] Recently, another anti-PD-L1 inhibitor, durvalumab, was proven highly effective after concurrent chemoradiotherapy in patients with stage III NSCLC.[2] Radiotherapy and chemotherapy do not only promote PD-L1 expression in tumors, but also the abscopal effect against tumor antigens.[9] Our patient showed a high PD-L1 expression in cancer cells; therefore, this could explain the patient's good response to the combination of ICI and chemoradiotherapy. Here, CD274 is linked to non-small cell lung carcinoma.